LB Pharmaceuticals Appoints Kaya Pai Panandiker As Chief Commercial Officer To Lead Commercial Strategy And Growth

LB Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders, announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer. Kaya Pai Panandiker brings over two decades of global biopharmaceutical experience, with a strong background in neuroscience commercialization and in launching and scaling major brands. Her leadership expertise spans multiple therapeutic areas, making her a valuable addition to LB Pharmaceuticals’ executive team as the company moves toward the next phase of growth.

“We are very pleased to welcome Kaya to LB Pharmaceuticals,” said Heather Turner, Chief Executive Officer of the company. “Her extensive experience in leading neuroscience brands and managing successful global product launches will be vital as we advance LB-102 toward registration and commercialization. Kaya’s ability to bridge scientific innovation with patient and market impact will play a central role in unlocking the full potential of LB-102 and driving long-term value creation for our stakeholders.”

Prior to joining LB Pharmaceuticals, Ms. Pai Panandiker served as Chief Commercial Officer at Neumora Therapeutics, a clinical-stage biopharmaceutical company developing precision medicines for brain diseases. Before that, she was Head of Commercial at Cerevel Therapeutics, which was acquired by AbbVie in 2024, and previously held the role of General Manager, Neuroscience at Lundbeck U.S. During her tenure at Lundbeck, she led the U.S. launches of REXULTI®, TRINTELLIX®, and the bipolar indication for ABILIFY MAINTENA®, all of which achieved blockbuster success across the company’s neuropsychiatry portfolio.

Commenting on her appointment, Ms. Pai Panandiker said, “It’s an exciting time to join LB Pharmaceuticals as we prepare to bring forward a differentiated therapy for schizophrenia and bipolar depression, with potential benefits extending to a wider range of neuropsychiatric disorders. LB-102 represents true innovation in an area with significant unmet need, and I look forward to collaborating with the LB team to make this important treatment available to patients.”

Ms. Pai Panandiker holds a Master’s degree in Public Policy from the University of Chicago and a Bachelor of Arts from the University of Wisconsin–Madison.